GlassScriptPhysician profile
Allison Cramer Brun
NPI 1952962771
$4,186.65
in general payments reported to CMS, 2019-2025
17 companies · $406 in 2025
The $406 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $157 · 2020: $328 · 2021: $1,069 · 2022: $1,078 · 2023: $569 · 2024: $581 · 2025: $406.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,556.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,555.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $610.31 | 2022-2025 | Xiidra, Miebo, Infuse |
| Sun Pharmaceutical Industries INC. | $554.84 | 2019-2025 | Cequa |
| Kala Pharmaceuticals, INC. | $501.29 | 2020-2022 | |
| Coopervision INC. | $457.72 | 2020-2025 | Myday Contact Lens, Misight Contact Lens |
| Novartis Pharmaceuticals Corporation | $442.91 | 2019-2023 | |
| Allergan, INC. | $382.46 | 2020-2022 | |
| Biotissue Holdings INC. | $347.11 | 2019-2025 | |
| Abbvie INC. | $157.75 | 2022-2024 | Lumigan, Vuity |
| Tarsus Pharmaceuticals, INC. | $141.71 | 2024-2025 | Xdemvy |
| Oyster Point Pharma, INC. | $133.19 | 2022-2025 | Tyrvaya |
| Alcon Vision LLC | $123.42 | 2021-2025 | Eysuvis, Tryptyr, Rocklatan |
| Dompe US, INC. | $109.56 | 2019-2025 | Oxervate |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $96.86 | 2019-2021 | |
| Johnson & Johnson Vision Care, INC. | $69.56 | 2023 | Acuvue |
| Plexus Optix, INC. | $23.71 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $20.91 | 2024 | Tepezza |
| Eyevance Pharmaceuticals LLC | $13.34 | 2023 | Flarex |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allison Brun listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.